Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 902 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Choice given Clear all
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease

NCT00392782
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, fludarabine phosphate, thiotepa, peripheral blood stem cell transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
9
States / cities
Tampa, Florida • Atlanta, Georgia • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 24, 2026, 5:05 PM EDT
Recruiting Not applicable Interventional

Successfully Achieving and Maintaining Euglycemia During Pregnancy for Type 2 Diabetes Through Technology and Coaching

NCT05662462
View directory record Official record
Conditions
Pre-Gestational Diabetes, Type2diabetes, Pregnancy in Diabetic, Pregnancy, High Risk
Interventions
DEXCOM G7 PRO Continuous Glucose Monitor, Patient mHealth app linked to a provider dashboard, Care team coaching for medical and social needs (HUB), Provider dashboard
Device · Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 24, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Results available

Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma

NCT03061188
View directory record Official record
Conditions
Advanced Solid Neoplasm, Aggressive Non-Hodgkin Lymphoma, Recurrent Solid Neoplasm, Refractory Mantle Cell Lymphoma, T-Cell Non-Hodgkin Lymphoma, Unresectable Solid Neoplasm
Interventions
Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study, Veliparib
Other · Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 24, 2026, 5:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

NCT04381650
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
TAK-981, Pembrolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
18
States / cities
Scottsdale, Arizona • Orange, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 24, 2026, 5:05 PM EDT
Withdrawn Not applicable Interventional

Protect Yourself: Abuse Prevention for People With Intellectual Disabilities

NCT03998605
View directory record Official record
Conditions
Abuse Prevention
Interventions
Abuse Prevention Program, Control Condition
Behavioral
Lead sponsor
Double S Instructonal Systems
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 24, 2026, 5:05 PM EDT
Recruiting Phase 1 Interventional

NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies

NCT07563829
View directory record Official record
Conditions
Metastatic Malignant Neoplasm
Interventions
NPX372
Drug
Lead sponsor
NextPoint Therapeutics, Inc.
Industry
Eligibility
19 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
6
States / cities
La Jolla, California • Baltimore, Maryland • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 24, 2026, 5:05 PM EDT
Terminated Phase 1 Interventional

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

NCT04682431
View directory record Official record
Conditions
Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Lung Adenocarcinoma, Pancreatic Cancer, Head and Neck Cancer
Interventions
PY159 Single agent dose level 1, PY159 Single agent dose level 2, PY159 Single agent dose level 3, PY159 Single agent dose level 4, PY159 Single agent dose level 5, PY159 Single agent dose level 6, PY159 Single agent dose level 7, PY159/Pembrolizumab Combination dose level 1, PY159/Pembrolizumab Combination dose level 2, PY159/Pembrolizumab Combination dose level 3, PY159/Pembrolizumab Combination dose level 4, PY159 Single agent dose expansion cohort, PY159/Pembrolizumab Combination dose expansion cohort 1, PY159/Pembrolizumab Combination dose expansion cohort 2, PY159/Pembrolizumab Combination dose expansion cohort 3, PY159/Pembrolizumab Combination dose expansion cohort 4, PY159/Pembrolizumab Combination dose expansion cohort 5, PY159/Pembrolizumab Combination dose expansion cohort 6
Drug
Lead sponsor
Ikena Oncology
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 24, 2026, 5:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Energy Expenditure During Seated, Seated Cycling, and Treadmill Walking Work Conditions (EE-Work)

NCT02118662
View directory record Official record
Conditions
Energy Expenditure
Interventions
Energy Expenditure during seated in an office chair, Energy Expenditure during seated and typing, Energy Expenditure during Treadmill walking work condition, Energy Expenditure during cycling work condition
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
21 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 24, 2026, 5:05 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating Verbal Communication in Structured Interactions: Theoretical and Clinical Implications

NCT06266403
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Structured Communicative Interaction, Clear Speech, Unstructured communicative interaction, Clear Speech Structured Communicative Interaction
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 24, 2026, 5:05 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Elucidation of Breast Milk Composition and Structure Over the First Year of Lactation: UC Davis Lactation Study

NCT01817127
View directory record Official record
Conditions
Healthy, Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
395 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2028
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 24, 2026, 5:05 PM EDT
Completed Not applicable Interventional

Ecosystem Focused Therapy in Post Stroke Depression

NCT01624402
View directory record Official record
Conditions
Depression, Stroke
Interventions
Education on Stroke and Depression (ESD), Ecosystem Focused Therapy (EFT)
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
3
States / cities
New York, New York • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 24, 2026, 5:05 PM EDT
Terminated Phase 1 Interventional

Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

NCT04887259
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
Interventions
LAVA-051, Interleukin 2
Biological
Lead sponsor
Lava Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • New York, New York • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 24, 2026, 5:05 PM EDT
Recruiting Phase 1 Interventional

Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors

NCT07128303
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
GS-5319, Carboplatin, Pemetrexed, Pembrolizumab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Boston, Massachusetts • New Brunswick, New Jersey • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

NCT03493854
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Cyclophosphamide, Doxorubicin, Docetaxel, Paclitaxel, Pertuzumab IV, FDC of Pertuzumab and Trastuzumab SC, Trastuzumab IV, Trastuzumab SC, Surgery, Post-operative Radiotherapy, Hormone Therapy
Drug · Procedure · Radiation
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Rockville, Maryland • Farmington, New Mexico • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 24, 2026, 5:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Collaborating to Implement Cross-System Interventions in Child Welfare and Substance Use

NCT03931005
View directory record Official record
Conditions
Substance Use, Implementation, Child Maltreatment, System Fragmentation
Interventions
Collaboration Decision Support Guide
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 24, 2026, 5:05 PM EDT
Completed Not applicable Interventional

MOBile Instruction for Low Back Pain (MOBIL)

NCT02777983
View directory record Official record
Conditions
Low Back Pain
Interventions
Educational Video App
Behavioral
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 50 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 24, 2026, 5:05 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Donor Lymphocyte Infusion After Alternative Donor Transplantation

NCT01027702
View directory record Official record
Conditions
Immunodeficiency
Interventions
Infusion of donor lymphocytes
Biological
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 30 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Oct 24, 2026, 5:05 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Early Intervention to Prevent Development of PTSD in Burn Survivors and Their Caregivers

NCT07656545
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Burns, Traumatic Injury, Acute Stress Disorder, Trauma and Stressor Related Disorders, Trauma and Stress Related Disorders, Stress Disorder, Stress Disorders, Post-Traumatic, Stress Disorders, Traumatic, Stress Disorders, Traumatic, Acute, Relationship, Social
Interventions
Promotion of Emotional Disclosure for Burns (PoED-B), minimally Enhanced Usual Care control (mEUC)
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 24, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients

NCT00157157
View directory record Official record
Conditions
Hemophilia A
Interventions
Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 6 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
17
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 24, 2026, 5:05 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

"Efficacy in Adolescents of Continued Behavior Modification Following a Six Month Sibutramine-based Weight Management Intervention"

NCT01023139
View directory record Official record
Conditions
Obesity
Interventions
Sibutramine
Behavioral
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
12 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2009 · Synced Oct 24, 2026, 5:05 PM EDT
Completed Not applicable Interventional Results available

Use of Behavioral Economics to Improve Treatment of Acute Respiratory Infections (Main Study)

NCT01454947
View directory record Official record
Conditions
Acute Respiratory Infections (ARIs)
Interventions
Clinical Decision Support (CDS): Accountable Justifications, Audit and Feedback: Peer Comparison, CDS Order Sets: Suggested Alternatives
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
55
States / cities
Anaheim, California • Bell, California • Commerce, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 24, 2026, 5:05 PM EDT
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

Consumption of More Ideal Food Options (COMIDA: Consumo de Opciones Más Ideales De Alimentos)

NCT03851458
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Initial in-person individual diet and exercise counseling (N vs. Y), Thrice weekly diet and exercise text messages (N vs. Y), Weekly telephone support (N vs. Y), Self-monitoring tools (N vs. Y) (for diet and weight)
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,785 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 24, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Comparing Self-paced Versus Moderate Intensity Physical Activity Recommendation for Midlife Adults

NCT05285748
View directory record Official record
Conditions
Physical Inactivity
Interventions
Self-Paced Intensity Physical Activity, Prescribed Moderate Intensity Physical Activity
Behavioral
Lead sponsor
Brown University
Other
Eligibility
50 Years to 64 Years
Enrollment
258 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 24, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

NCT02118285
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Interventions
Fludarabine, Cyclophosphamide, NK cells, IL-2, INCB024360
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 24, 2026, 5:05 PM EDT